287 related articles for article (PubMed ID: 15254675)
1. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
Coskun U; Bukan N; Sancak B; Günel N; Ozenirler S; Unal A; Yucel A
Neoplasma; 2004; 51(3):209-13. PubMed ID: 15254675
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y
Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341
[TBL] [Abstract][Full Text] [Related]
5. Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis.
Junbo H; Li Q; Zaide W; Yunde H
In Vivo; 1999; 13(2):177-80. PubMed ID: 10363175
[TBL] [Abstract][Full Text] [Related]
6. Serum concentrations of hepatocyte growth factor in breast cancer patients.
Taniguchi T; Toi M; Inada K; Imazawa T; Yamamoto Y; Tominaga T
Clin Cancer Res; 1995 Sep; 1(9):1031-4. PubMed ID: 9816076
[TBL] [Abstract][Full Text] [Related]
7. The significance of serum hepatocyte growth factor levels in planning follow-up of postoperative jaundice-free patients with biliary atresia.
Uchida K; Inoue M; Otake K; Yoshiyama S; Toiyama Y; Hiro J; Araki T; Miki C; Kusunoki M
J Pediatr Surg; 2006 Oct; 41(10):1657-62. PubMed ID: 17011264
[TBL] [Abstract][Full Text] [Related]
8. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ; Adachi I
Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
[TBL] [Abstract][Full Text] [Related]
9. The role of a protease inhibitor against hepatectomy.
Gotohda N; Iwagaki H; Ozaki M; Konishi M; Nakagohri T; Takahashi S; Yagi T; Kinoshita T; Tanaka N
Hepatogastroenterology; 2006; 53(67):115-9. PubMed ID: 16506388
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
11. Serum hepatocyte growth factor before and after resection for hepatocellular carcinoma.
Hu RH; Lee PH; Yu SC; Sheu JC; Lai MY
Hepatogastroenterology; 1999; 46(27):1842-7. PubMed ID: 10430357
[TBL] [Abstract][Full Text] [Related]
12. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
[TBL] [Abstract][Full Text] [Related]
13. Serum big endothelin-1 levels in female patients with breast cancer.
Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
[TBL] [Abstract][Full Text] [Related]
14. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection.
Chau GY; Lui WY; Chi CW; Chau YP; Li AF; Kao HL; Wu CW
Eur J Surg Oncol; 2008 Mar; 34(3):333-8. PubMed ID: 17218078
[TBL] [Abstract][Full Text] [Related]
15. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W
Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
[TBL] [Abstract][Full Text] [Related]
16. Tumor HGF lacks prognostic significance in Mexican breast cancer patients.
Pruefer FG; Unger-Saldaña K; Mohamier L; Ramírez M; Suárez J; Ramirez MT; Maldonado V; Meléndez-Zajgla J
J Exp Clin Cancer Res; 2006 Sep; 25(3):357-64. PubMed ID: 17167976
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients.
Ahmed HH; Metwally FM; Mahdy ES; Shosha WG; Ramadan SS
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):958-65. PubMed ID: 22953646
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma.
Zhao J; Hu J; Cai J; Yang X; Yang Z
Chin Med J (Engl); 2003 May; 116(5):772-6. PubMed ID: 12875699
[TBL] [Abstract][Full Text] [Related]
19. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.
Bellone S; Watts K; Cane' S; Palmieri M; Cannon MJ; Burnett A; Roman JJ; Pecorelli S; Santin AD
Gynecol Oncol; 2005 Jul; 98(1):92-8. PubMed ID: 15904949
[TBL] [Abstract][Full Text] [Related]
20. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]